172 related articles for article (PubMed ID: 31094130)
1. Plasma Cell Leukaemia: A Rare Yet Aggressive Plasma Cell Dyscrasia With A Very Poor Response To Conventional Therapy.
Khan N; Raza SS; Khan UI; Hafez I; Abdullah MA; Hassan M; Rukh Hijaz AS; Hussain AK; Nadeem MD
J Ayub Med Coll Abbottabad; 2019; 31(2):272-275. PubMed ID: 31094130
[TBL] [Abstract][Full Text] [Related]
2. Primary plasma cell leukemia occuring in the young.
Raj RS; Najeeb S; Aruna R; Pavithran K; Thomas M
Indian J Cancer; 2003; 40(3):116-7. PubMed ID: 14716116
[TBL] [Abstract][Full Text] [Related]
3. A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia.
Galakhoff N; Leven C; Eveillard JR; Tempescul A; Kerspern H; Aubron C; Buors C; Lippert É; Carré JL; Padelli M
Biochem Med (Zagreb); 2020 Feb; 30(1):010801. PubMed ID: 31839726
[TBL] [Abstract][Full Text] [Related]
4. Early relapse after complete remission of primary plasma cell leukaemia manifesting clonal evolution: A case report.
Nyunt WWT; Abdul Jalil D; Zakariah NA; Abdul Karim N; Mohd Idris MR; Nasuruddin DN; Salwati SHUIB; Alauddin H; Tumian NR; Leong CF; Abdul Wahid SFS
Malays J Pathol; 2020 Apr; 42(1):143-150. PubMed ID: 32342945
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
6. Primary Plasma Cell Leukaemia: Case report and review of the literature.
Singh S; Rath A; Yadav S
Sultan Qaboos Univ Med J; 2018 Aug; 18(3):e397-e401. PubMed ID: 30607287
[TBL] [Abstract][Full Text] [Related]
7. [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].
Jurczyszyn A; Zawirska D; Skotnicki AB
Przegl Lek; 2011; 68(6):320-5. PubMed ID: 22039670
[TBL] [Abstract][Full Text] [Related]
8. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
[TBL] [Abstract][Full Text] [Related]
9. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
Telek B; Méhes L; Batár P; Kiss A; Udvardy M
Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
[TBL] [Abstract][Full Text] [Related]
12. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
Jimenez-Zepeda VH; Dominguez-Martinez VJ
Int J Hematol; 2009 Apr; 89(3):259-268. PubMed ID: 19326058
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report.
Wöhrer S; Ackermann J; Baldia C; Seidl S; Raderer M; Simonitsch I; Drach J
Hematol J; 2004; 5(4):361-3. PubMed ID: 15297854
[TBL] [Abstract][Full Text] [Related]
14. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell leukemia: from biology to treatment.
Jelinek T; Kryukov F; Rihova L; Hajek R
Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
[TBL] [Abstract][Full Text] [Related]
16. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
17. Two cases of nonsecretory multiple myeloma presenting as primary plasma cell leukemia.
Takahashi T; Kanno S; Itoh H; Yoshimoto M; Tsujisaki M; Fujino M
Intern Med; 2014; 53(18):2121-5. PubMed ID: 25224200
[TBL] [Abstract][Full Text] [Related]
18. Primary plasma cell leukemia presenting as a thoracic mass.
Igala M; Bopaka RG; Khtabi W; Benchekroun S; Quessar A
Pan Afr Med J; 2014; 19():39. PubMed ID: 25667701
[TBL] [Abstract][Full Text] [Related]
19. Primary Plasma Cell Leukemia: Identity Card 2016.
Musto P; Simeon V; Todoerti K; Neri A
Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
[TBL] [Abstract][Full Text] [Related]
20. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.
Gavriatopoulou M; Musto P; Caers J; Merlini G; Kastritis E; van de Donk N; Gay F; Hegenbart U; Hajek R; Zweegman S; Bruno B; Straka C; Dimopoulos MA; Einsele H; Boccadoro M; Sonneveld P; Engelhardt M; Terpos E
Leukemia; 2018 Sep; 32(9):1883-1898. PubMed ID: 30038381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
